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1.  INTRODUCTION 
1.1 MEDICINAL PLANTS 
Medicinal plants were the primary health care agents a long time before the 
advent of modern medicine and have been used medicinally for thousands of 
years by cultures all over the world (Barnes et al., 2007).  
The first written information about plants used as drugs originates from the 
Sumerians and Akkadians (3rd millennium BC). Until the beginning of the 
19th century, drugs were used in the form of powders, simple extracts, or 
tinctures. In 1803 Sertürmer isolated morphine from opium and this crucial 
discovery ushered in a new era in the history of medicine characterized by 
the isolation and chemical identification of pharmacologically active 
compounds from crude drugs (Samuelsson, 1999). In the following decades 
many other important compounds were identified; nevertheless, taxonomy 
and morphology of plants dominated pharmacognosy research and the main 
object was still botanical identification of crude plant-derived drugs.  
Only after the Second World War organic chemistry became dominant and 
pharmacognosists devoted their time to isolation and structure determination 
of different compounds. Their main concern was with molecules derived from 
plants, very little was done on animals, insects or microorganisms. Therefore, 
today the main constituents of all important medicinal plants have been 
isolated and their structures determined (Samuelsson, 1999). As a result of 
knowledge gained from studying the mechanisms of action of chemicals first 
isolated from medicinal plants, many more modern drugs were synthesized, 
such as aspirin, digitalis, morphine, and quinine. This fact is well recognized 
even by today’s biomedical community that continues to send explorers to 
the corner of the earth to find new plant-related cures for our maladies 
(Matthews et al., 1999).  
However, from about the beginning of the 20th century up to the 1970s the 
usage of medicinal plants had been in decline in most developed Western 
countries. Industrialisation and urbanisation and their associated rejection of 
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traditional values and system were the cause of the decline in popularity. 
Interesting is that a similar decline in the use of medicinal plants did not occur 
in the more developed Asian countries as Japan, despite considerable 
industrialization (Wills et al., 2000).  
In the last two decades an opposite trend was observed, since a general 
disillusionment with conventional medicines coupled with the desire for 
‘natural’ lifestyle had resulted in an increasing utilisation of complementary 
and alternative medicine (CAM) as well as in a larger demand of medicinal 
plants across the developed world (Matthews et al., 1999; Barnes et al., 
2007).  
Nowadays about 40% of the modern drugs in use are of natural origin and 
medicinal plants have a great importance because a great proportion of 
natural products derived from plants (Samuelsson, 1999). 
Although even if the estimates of expenditure on herbal market vary and 
make the comparisons between countries very difficult, data generally show 
that the global market for herbal products has grown rapidly in the last two 
decades (Brevoort, 1998; Barnes et al., 2007). 
In the European Union retail sales of herbal products were estimated to be 
US$ 7000 million in 1996 (Blumenthal, 1998). Greatest sales were reported 
in Germany with 45 % of the European Union market and France (30%), 
followed by Italy (11%), the UK and Spain (each at 5%) (Wills et al., 2000). In 
1997, total sales of herbal products (using wholesale prices) were US$1.8 
billion in Germany and US $1.1 billion in France. In the UK, retail sales of 
herbal products are reported to have increased by 43% in the period from 
1994 to 1998, with retail sales of licensed herbal products reported to be £50 
million in 1998 (House of Lords, 2000). In the USA, annual retail sales of 
herbal medicines were estimated to be US$ 1.6 billion in 1994 (Brevoort, 
1996), and almost 4 billions in 1998 (Brevoort, 1998). However, since then 
the US market has levelled off and in some cases declined (Rogers, 2005). 
Asian sales are estimated at US$ 4.4 with Japan contributing to nearly half of 
this total (Wills et al., 2000). 
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Medicinal herbs versus conventional drugs 
Medicinal plant products are very similar to conventional drugs for many 
aspects; on the other hand there are also important differences.  
Some phytopharmaceuticals have full therapeutic equivalence with 
chemotherapeutics, as was shown by several comparative clinical trials on 
the species Crataegus, Silybum, Ginkgo, Hypericum, Sabal Urtica, Kava-
Kava, Allium sativum, Valeriana, Aesculus, Echinacea and Viscum, which 
had the simultaneous advantage of being devoid of any adverse effects 
(Wagner et al., 1999). But not even all medicinal plants are free of adverse 
effects. As conventional drugs, they can potentially provoke adverse effects 
and also be toxic. In fact, for herbal ingredients, along with a range of 
toxicities, also allergic, cardiac, hepatic, irritant and purgative effects have 
been documented in humans and animals (Barnes et al., 2007).  
While many conventional drugs or their precursors are derived from plants, 
there is a fundamental difference between administering a pure chemical and 
the same chemical in a plant matrix, because of the elevated chemical 
complexity of the medicinal plant product respect to the pure chemical. It is 
possible that this chemical complexity gives an advantage to the plant 
product (Wills et al., 2000).  
However, it has not been possible to develop commercially profitable 
methods of synthesis for all interesting molecules found in medicinal plants, 
even if they have been synthesized in the laboratory, because most of them 
have a very complex chemical structure (Samuelsson, 1999). 
Certainly, the chemical complexity of medicinal plant products, which 
introduces many variables, is difficult to manage in scientific research. This is 
also the reason for the absence of scientific evidences for the clinical efficacy 
of a lot of plant ingredients (Barnes et al., 2007).  
Unlike conventional drugs, phytopreparations are applicable primarily for the 
treatment of moderate or moderately severe diseases; it is also evident that 
most phyto-preparations exert their effects at a much lower concentration, up 
to ten times less or more. This difference can be explained by synergistic 
effects caused by the various compounds in a raw medicinal plant or extract. 
Another important difference is that many phytopreparations exhibit no 
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immediate pharmacologic or therapeutic effects and achieve their optimal 
efficacy only after long-term treatment (Wagner, 1999). This effect has been 
demonstrated in an in vivo study with a Crataegus extract, which resulted in 
an increase in myocardial blood circulation only after an application of three 
weeks (Mävers and Hensel, 1974).  
Finally, herbal medicines are used in a science-based approach, like 
conventional drugs, for the treatment and prevention of disease, known as 
(rational) phytotherapy. However, there is another approach to the use of 
herbal medicines in a holistic manner and mainly on the basis of their 
empirical and traditional uses (Barnes et al., 2007). 
Legislation 
Herbal medicines are regulated at present in the European Community by 
Directive 2004/24/EC, which came into effect on 30 October 2005. This 
Directive amended Directive 2001/83/EC, the Community code on medicinal 
products for human use and introduced the Traditional Herbal Medicines 
Registration Scheme, which simplifies the registration compared to the 
former rule. Products registered under the scheme will however need to meet 
specific standards of safety and quality and to be accompanied by agreed 
indications and systematic patient information allowing the safe use of the 
product. In the seven-year transitional period Herbal medicine products will 
not need to be registered until 30 April 2011. 
To advance the state of herbal medicine, European trade associations 
formed the European Scientific Cooperative for Phytotherapy (ESCOP) under 
the auspices of the European Economic Community. ESCOP published a 
series of plant species monographs for European Community marketing 
authorization (Taylor, 1996). 
While in Europe many herbal medicine products are closely controlled and 
are available only by prescription in the United States they are readily 
available through a variety of retail outlets, since the majority of medicinal 
herbs and their products are regulated like foods as dietary supplements, 
under the 1994 Dietary Supplement Health and Education Act.  
 7 
Safety 
Herbal medicinal products are being used increasingly by the general public 
on self-selection basis to either replace or complement conventional 
medicines.  
In terms of safety, it is a popular conception that because herbs are ‘natural’ 
then they must also be safe. This is a misconception, and it is emphasised 
that some herbal ingredients have the potential to induce adverse effects, 
when overdosed or incorrectly used, whilst some are decidedly toxic (Barnes 
et al., 2007). In the United Stated the marketing and use of these "natural" 
alternatives were greatly facilitated, where medicinal herbs and other 
botanical products figure in the definition of dietary supplements (Matthews et 
al., 1999). Against this background of increasing usage of herbal medicines 
by public, that isn’t adequately informed, a number of major public health 
issues have raised concerns about these products and have highlighted the 
need for healthcare professionals to have up-to-date scientific information on 
the quality, safety and efficacy of these products (Barnes et al., 2007). 
Another problem is that, on the market of many countries, the majority of 
herbal medicinal products are only available as unlicensed products (Barnes 
et al., 2007). At least until April 2011, as in the case of European Community, 
we will find unregulated herbal medicine products available with a quality that 
will not have been assessed by a Regulatory Authority. 
In the absence of adequate standardization and quality control, both 
consumers and responsible producers of medicinal herbs are at risk. 
Consumers must have a consistent product of high quality to effectively 
achieve safe, beneficial effects from one formulation to another. Responsible 
producers are at risk when inconsistent or ineffective products damage the 
reputation of the industry. 
Other concerns regarding the use of medicinal herbs include the possibility of 
herb/herb or herb/drug interactions and allergic reactions. Because 
interactions are not systematically documented and such reports are largely 
anecdotal, concern has been expressed regarding potential interactions 
involving prescription drugs (Matthews et al., 1999). Also a problem is 
represented by the traditional practises, such as substituting one ingredient 
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for another one for which similar action has been reported (Barnes et al., 
2007). 
To contrast these world-wide safety concerns for herbal medicine products, 
the World Health Organisation (WHO) conducted a recent global survey on 
the regulatory control of herbal medicines and has reported findings from 141 
countries (Anon., 2005). The WHO resolved to provide technical support for 
the development of methodologies to monitor and ensure product safety, 
efficacy and quality. WHO guidelines have recently been developed in a 
number of important areas, including consumer information, pharmaco-
vigilance, and good agriculture and collection practices (GACP).  
Plant material quality 
In order to ensure high quality herbal medicinal product and reproducibility in 
experiments, it is important to control the starting material taking some 
dispositions.  
First, medicinal plants have to be correctly authenticated, therefore herbal 
ingredients have to be referred to their binominal Latin names of genus and 
species. It’s all the way possible although a correct authentication that 
different batches of the same herbal ingredient differ in quality, this can be 
due to a number of aspects like environmental factors, intra- and inter-
specific variability, harvesting time, the type of plant organ, post-harvest 
conditions and processing and the substitution of herbal ingredients (Barnes 
et al., 2007). 
The starting material has to be free from contaminants, or at least with 
concentrations under the tolerated threshold values. There are different kinds 
of contaminants of medicinal plants: microbial organisms, pesticides, foreign 
organic matter, fumigants, toxic metals and other substances like endotoxins 
and mycotoxins (Barnes et al., 2007).  
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Wild plants or cultivated plants? 
Besides economic factors the choice between collection from wild plants and 
cultivation may be influenced by environmental considerations. A high 
demand for a certain wild-growing species can cause its extinction. For this 
reason in the future many medicinal plants, which at present are wild growing 
species, may have to be cultivated (Samuelsson, 1999). 
Medicinal plants may be prepared from wild or cultivated. There are several 
advantages in growing medicinal plants rather than collecting the drug from 
the wild. Environmental parameters, such as soil conditions, shade, moisture, 
and irrigation, can be controlled, and plant disease can be more readily 
treated. In this way, high quality starting material can be producted to ensure 
optimum plant development of the plants, which are approximately at the 
same stage of development and grow closely together in smaller areas. All 
these factors facilitate the production of medicinal plants with high quality 
standards. The method of production used in each individual case is largely 
determined by economic factors. 
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1.2 ECHINACEA SPP. 
Botany 
The genus Echinacea Moench belongs to the Family Asteraceae (Subfamily 
Asteroideae) and is classified in the Tribe Heliantheae (Karis and Ryding, 
1994). To date the classification in a Sub tribe is not definitely clarified and 
has already been reviewed several times. In 1977 the genus Echinacea was 
attributed by Stuessy to the Sub tribe Heliantheae, together with Rudbeckia, 
Dracopsis and Ratibida. 
Robinson divided the Tribe Heliantheae into 35 Sub tribes and ranked the 
genus Echinacea to the Sub tribe Ecliptinae, whereas the genera Rudbeckia, 
Dracopsis and Ratibidia were ranked in the new Sub tribe Rudbeckiinae. 
Problematic was the vague delimitation between the Sub tribe Ecliptinae and 
the other Sub tribes, so that Karis (1993) presented an amendment of the 
taxonomic nomenclature after Robinson. Karis divided the Tribe Heliantheae 
into 10 Sub tribes and classified the genera Echinacea in the Sub tribe 
Rudbeckiinae. In this way he re-established a close relationship with the 
genera Rudbeckia, Dracopsis and Ratibida. A common characteristic of all 
four genera is the conical arched inflorescence, which in Echinacea is spiny 
via the spiky receptacle bracts (Bauer and Wagner, 1990).  
This morphologic characteristic gives the name to this genus. The name 
“Echinacea” is derived from the Greek word “echinos”, which means 
hedgehog or sea urchin. 
The classification of Echinacea in the Sub tribe Rudbeckiinae was criticised 
because of the latest phylogentetic researches. cDNA and IST sequences 
were analyzed with different species among the tribe Heliantheae (Urbatsch 
et al. 1995, 2000). The two trails demonstrate, that the genera Echinacea 
show no close phylogenetic relationship with the other genera of the Sub 
tribe Rudbeckiinae, but are closer to the genera Sanvitalia and other species 
of the subtribe Ziniinae. 
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For this reason Urbatsch suggested a transfer of the genera Echinacea to the 
Sub tribe Zinniinae. The different classifications show that in the genus 
Echinacea, depending on the taxonomic analysis, other relationships result. 
All species of the genus Echinacea are persistent and perennial herbs. They 
tend to hybridization and therefore they generate a lot of intermediates, what 
leaded in the past to controversially taxonomic classifications.  
Cronquist (1945, 1980) described four Echinacea species, E. pallida var. 
angustifolia, E. pallida var. pallida, E. atrorubens var. atrorubens, E. 
atrorubens var. paradoxa, E. laevigata and E. purpurea. 
At present the most widespread nomenclature derives from McGregor 
(1968). He designed an identification key for the genus according to 
morphological, anatomical, ecological and cytological features and he divided 
the genus in 9 species and two varieties: 
• E. angustifolia DC. var. angustifolia 
• E. angustifolia DC. var. strigosa McGREGOR 
• E. atrorubens NUTT. 
• E. laevigata (BOYNTON & BEADLE) BLAKE 
• E. pallida (NUTT.) NUTT. 
• E. paradoxa (NORTON) BRITTON var. paradoxa 
• E. paradoxa (NORTON) BRITTON var. neglecta McGREGOR 
• E. purpurea (L.) MOENCH 
• E. simulata McGREGOR 
• E. sanguinea NUTT. 
• E. tennesseensis (BEADLE) SMALL 
At last Binns (2001) conducted a taxonomic review of the genus Echinacea 
by means of morphological considerations (Table 1). As according to this 
review E. purpurea differs most from the other species, a Subgenus for 
Echinacea was created. Furthermore three other species were characterized, 
E. pallida, E. atrorubens and E. laevigata, which were united in the Subgenus 
Pallida. The other species described by McGregor were defined as varieties 
of E. pallida or E. atrorubens . 
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The new classification is similar in many considerations to the disquisition on 
taxonomy by Cronquist (1945). In this thesis McGregor’s denomination is 
used because the taxonomic classification by Binns has not yet been 
enforced.  
 
Subgenus Species Variety 
Echinacea 
E. purpurea (L.) Moench nom. 
cons. prop.  
 
E. pallida (Nutt.) Nutt.  
var. pallida 
var. tennesseensis (Beadle) Binns 
B.R. Baum & Arnason 
var. angustifolia (DC.) Cronquist 
var. sanguinea (Nutt.) Gandhi and 
Thomas 
var. simulata (McGregor) Binns B.R. 
Baum & Arnason 
E. atrorubens Nutt. 
var. atrorubens 
var. paradoxa (J.B. Norton) Cronquist 
var. neglecta (McGregor) Binns, B.R. 
Baum & Arnason 
Pallida 
E. laevigata  
(C.L.Boynton & Beadle) Blake 
nom. cons. prop. 
 
Table 1. Taxonomic classification of the genus Echinacea by Binns (2001). 
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Echinacea angustifolia  
Echinacea angustifolia, commonly referred to as the narrow-leafed purple 
coneflower, is native to the North America and distributed on dry prairies from 
Texas to Saskatchewan and from west of the Rocky Mountain to Minnesota 
(McGregor, 1968). Among the genus Echinacea it is generally considered the 
species with the highest therapeutic value, therefore it has a high market 
value, but there are no clinical tests that sustain scientifically its superiority 
(Pepping, 1999). 
E. angustifolia has stiff, bristly hairs on its leaves, which are alternate, simple, 
dark green and narrowly lance shaped. Basal leaves are 5-30 cm long and 1-
4 cm wide, while cauline leaves length range from 4-15 cm and width from 
0.5-4 cm. The plant has one or more rough-hairy, 10-50cm high, and mostly 
unbranched stems, which ascends from a light brown and little fibrous 
vertical taproot. One or more flowering stems bear the large (4-7.5 cm) 
purple or pale pink ray flowers which bloom from early summer to early fall. 
The disk flowers are 5-lobed, brownish-purple, and situated among stiff 
bracts. Pollen grains are yellow. Fruits are small, dark, 4-angled achenes. 
Propagation by achenes is not easy done to the poor germination, tedious 
nurturing can be eliminated and stronger plants obtained by propagation by 
division. In traditional cultivation system the taproot of cultivated E. 
angustifolia is harvested three-to-four years from sowing (Mistríková and 
Vaverková, 2007). 
Echinacea is a very popular herb throughout the Western countries, 
particularly in Europe and in North America (Barret, 2003), further it’s 
becoming more popular also in Australia (Wilkinson and Simpson, 2001). 
Echinacea spp. is interesting above all for its immunomodulatory effects, 
particularly to reduce the symptoms and duration of colds, influenza and 
other upper respiratory tract infections (Barnes et al., 2007). Further 
Echinacea is also grown for the ornamental value, especially for its showy 
flowers. 
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There are three species of the genus Echinacea, which are commonly used 
for medicinal purposes: E. angustifolia D.C. (De Candolle) var. angustifolia, 
E. pallida (Nutt.) Nutt., and E. purpurea (L.) Moench. 
Echinacea was used by indigenous Americans for internal use against colds, 
sore throats, infections, coughs, toothache and inflammations and external 
use to treat burns, snake and insect bits (Hobbs, 1994, Kindscher, 1992). 
The use of Echinacea passed to the European settlers in the 18th century and 
was mentioned for the first time in 1762 by Clayton in the Flora Virginica 
(Flannery, 1999).  
In Europe Echinacea species were introduced first as decorative plants and 
later they became very popular as medicinal plants, and supplies derived 
from wild native American plants did not meet with the increased demand 
(Galambosi, 2004). Echinacea seeds were taken to Europe and became 
widely cultivated especially in Germany by the Madaus company and in 
France. Mistakenly instead of E. angustifolia seeds, those of E. purpurea 
were cultivated in Europe. For this reason studies published before 1987 
must be viewed with caution, considering the current species evaluation. 
Many of the early studies on E. angustifolia and E. purpurea were probably 
actually conducted on E. pallida (Bauer and Wagner, 1987). 
Data on the current cultivation area of Echinacea in Europe are rough 
estimations because there are no data available in national official statistics. 
The estimated planted area of the three main Echinacea species in Europe is 
250 to 300 ha. Germany shows the biggest area, with about 85 ha, followed 
by France, Italy, Poland and Hungary with about 30 to 50 ha, Holland and 
Sweden with about 13 to 20 ha and Switzerland, Spain and Finland with 3 to 
5 ha (Galambosi, 2004). 
Market 
With the advent of modern medicine, a range of traditional treatments came 
under question and, in 1909, Echinacea was removed as an approved 
therapeutic agent by the American Medicial Association. Scientific research 
into the composition and pharmacological properties of Echinacea was 
commenced in Germany in the 1930s and studies over the next 30 years 
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have provided a solid base which has supported the revival of Echinacea 
throughout the western world (Barrett, 2003; Galambosi, 2004). 
At present, natural health products derived from Echinacea plant material 
have a leader position in a trend toward preventive health care and 
alternatives to synthetic pharmaceuticals in Europe and in the United States 
(Binns et al., 2004).  
About ten years ago, Echinacea spp. was among the top 10 herbs sold in the 
US market (Brevoort, 1998), where annual sales were estimated to range 
from more than $200 million (Blendon et al., 2001) to $300 million (Brevoort, 
1998). According to the stagnant and even negative trend in the US 
medicinal plant market reported (Rogers, 2005), also Echinacea sales have 
declined about 20% in 2000 and 2001 in the US market (Blumenthal, 2001; 
Blumenthal 2002). 
In Europe in 1998 Echinacea was reported among the ten most important 
medicinal plant sold in Europe with annual sales of about $120 million 
(Commonwealth Secretariat, 2001). Echinacea product manufacturing in 
Europe is dominated by German companies and the largest market in 
Europe is Germany.  
Different types of Echinacea health products are found on the market: crude 
extracts or tinctures from root and aerial parts, freeze dried ethanolic or 
hydroalcoholic extracts, whole or powdered dried leaves capsules or tablets 
from dried roots (Li, 1998; Barret, 2003). They are mainly manufactured from 
the species E. purpurea, and E. angustifolia (Li and Wardle, 2001). 
Accordingly to the stagnant and even negative trend in the US medicinal 
plant market reported (Rogers, 2005), also Echinacea sales have declined 
about 20% in the 2000 and 2001 un the US market (Blumenthal, 2001; 
Blumenthal, 2002). 
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Plant material quality 
One of the reasons for the significant lack of well-characterized plant material 
is the lack of clarity in the taxonomic classification and identification of 
Echinacea (Binns et al., 2004). Phytochemical reports have been made for 
the three medicinally important taxa. Further many factors affect the level of 
active ingredients, including cultivar, species, number of years of cultivation 
growing conditions and environment, processing and harvesting method, and 
which plant part is considered (Li and Wardle, 2001). It has been also 
observed, that there are large differences between comparable products from 
different manufacturers.  
Like for many other herbal medicines, it is not yet clear how and which of 
Echinacea’s complex range components exert direct or synergistic effects 
(Bauer, 1999a). This lack of clarity produces difficulty in standardizing plant 
components and functional end products of Echinacea.  
Pharmacological properties 
The most important pharmacological property of Echinacea is its 
immunomodulating action. In vitro studies have demonstrated the stimulation 
of various immune cells such as macrophages, other monocytes, and natural 
killer cells (Bauer, 1999a; Rininger et al., 2000). The immunomodulatory 
activity, in the various Echinacea preparations can be ascribed to four major 
groups: polysaccharides (Wagner, 1999), alkylamides, glycoproteins (Bauer 
1999a), and caffeic acid derivatives (CADs). It has been shown, that 
Echinacea provides has real benefits in reduction of acute upper respiratory 
infections, even if they appear moderate. However, the evidence of efficacy 
is not definitive as studies have included different parameters such as type of 
patient group, different preparations and dosages (Barnes et al., 2007). 
There is still debate as to the relative importance of the different chemical 
groups, with some having the view that substantial synergistic effects are 
occurring among the groups (Wills et al., 2000). 
Further Echinacea preparations have been reported to show anti- 
inflammatory effects (Wagner 1999), anti-fungal activity (Binns et al., 2004), 
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anti-bacterial activity, antiviral effects, and insecticidal activity (Clifford et al., 
2002). 
Caffeic acid derivatives (CADs) 
Caffeic acid glycosides (e.g. echinacoside, and verbacoside), caffeic acid 
esters of quinic acid (e.g. chlorogenic acid, isocolorogenic acid, and cynarin) 
and of tartaric acid (e.g. caftaric acid, and cichoric acid) are revealed in 
Echinacea. Varying mixtures of caffeic acids are present in the three species. 
The major caffeoyl constituent of the roots of E. angustifolia was identified as 
echinacoside (Pietta et al., 1998; Stoll et al., 1950). This characteristic 
distinguish this species from both E. purpurea and E. pallida (Harborne and 
Williams, 2001). Molecular structures of some CADs are reported in Figure 1. 
 
 
Polysaccharides 
The crude polysaccharide fraction from the roots of E. angustifolia has been 
isolated but the individual components have not been characterized 
completely (Wagner et al., 1985). Much more research on polysaccharides 
has been done in E. purpurea, from which two molecules with 
immunostimulatory properties have been isolated in vitro and in vivo: 4-O-
methyl-glucuronoarabinoxylan and an acid arabinorhamnogalactan (Bauer 
and Wagner, 1991). The acidic arabinorhamnogalactan from E. purpurea is 
now produced biotechnologically on an industrial scale (Wagner, 1999). 
Figure 1. Chemical structures of caffeic acid and some of its derivatives.  
Echinacoside 
Cichoric acid 
 
Chlorogenic acid 
Cynarin 
 
Caftaric acid 
 
Caffeic acid 
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Glycoproteins 
Glycoproteins have been implicated in the immunostimulatory activity of 
Echinachea extracts by inducing cytokine production and by their mitogenic 
activity (Bauer, 1993 and 1994). In E. angustifolia roots three glycoproteins 
with molecular weights between 17.000 u and 30.000 u, have been isolated, 
containing about 3% protein.  
Alkylamides 
Alkylamides are fatty acid amides containing one ore more double bonds that 
may be accompanied by up to three acteylenic linkages. Alkylamides are 
characteristic constituents of roots of E. angustifolia. In this species the 
alkylamides reported are mainly of the acetylenic type, together with a small 
number of purely olefinic structures. Some 15 alkylamides have been 
characterized in roots of E. angustifolia (Bauer et al., 1989). 
Echinacea products also contains a number of compounds without proven 
immunostimulating action 
Alkaloids 
In the extracts of E. angustifolia (and E. purpurea) two pyrolizidine alkaloids 
have been isolated, tussilagine and isotussilagine (Röder et al., 1984). The 
major constituent tussilagine is present as 0.006% of dried roots of E. 
angustifolia (Britz-Kirstgen, 1985).  
Essential Oils 
The main essential oils components in Echinacea tissues irrespective of 
species, are camphene, β-pinene, and limonene, together with other volatiles 
such as acetaldehyde, dimethyl sulphide, and hexanal (Harborne and 
Williams, 2001).  
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1.3 ANALYTICAL METHODS  
Storage of plant material  
Medicinal plant preparations are more and more under pressure by 
consumers and regulatory authorities to be standardized for active principles 
(Wills et al., 2000). But standardisation is no easy task especially for 
medicinal plants because often their pharmacological activity is due to a wide 
range of compounds. Moreover the situation is complicated by the fact that 
the relative importance of the different constituents is not known. Different 
marker compounds have been proposed for standardisation purposes. It was 
suggested that Echinacea preparations should be standardized for their 
contents on the lipophilic alkylamides and the more polar phenolic 
compounds (Bauer, 1999a). Since echinacoside and cynarin are the major 
polar constituents in the roots of E. angustifolia they are frequently used for 
the standardization of corresponding Echinacea preparations (Wölkart et al., 
2004). 
When well chosen marker compounds are a helpful tool for standardisation, 
however, the great variations in active principles remains. For this reason it’s 
important that factors that induce variation, such as cultivation practices, 
plant parts, plant species, and harvest time, are unified as much as possible. 
For example different harvest times have been shown to provoke great 
variations in the levels of active principles; for cichoric acid levels differences 
up to 75% have been shown in tops of E. purpurea (Perry et al., 2001).  
Further, at many points in post-harvest handling (drying and processing chain 
that converts the freshly harvested Echinacea to a manufactured product), 
active constituents can be lost (Wills and Stuart, 1999). So, it’s important to 
determine the stability of active compounds first of all in the fresh and dried 
plant material, but also in extracts and in the final products. 
Preservation of plant material 
Only a in few cases it is possible to work up harvested material immediately, 
so as to obtain pure compounds or concentrates of the constituents. Mostly 
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this cannot be done on the spot, and the plant material must first be 
preserved so that the active compounds will remain unchanged during 
transport and storage. 
In living cells barriers, like membranes, keep low molecular-weight 
compounds and enzymes apart. When the plant dies, the barriers are quickly 
broken down and the enzymes then get the opportunity to promote various 
chemical changes in the other cell constituents, e. g. by oxidation or 
hydrolysis. Preservation aims at limiting these processes as far as possible. 
Drying 
The most common method for preserving plant material is drying. Since 
enzymatic processes take place in aqueous solution, the rapid water removal 
from the cell will largely prevent degradation of cell constituents. During this 
process the water content of the plant material is reduced to about 10% or 
less. Drying is promoted by high temperatures and low relative humidity, but 
temperature has to be controlled since active principles can be sensitive to 
heat and enzymatic activity can increase. For this reason, the choice of 
temperature must be a balancing act between the necessity for quick drying 
and the sensitivity to heat of the constituents and enzymatic kinetics. 
Generally low drying temperatures, between 30ºC and 50ºC, are chosen, 
since heat sensitive compounds are protected (Müller and Heindl, 2006). 
In a dried drug enzymes are not destroyed but only rendered inactive due to 
the low water content. As soon as water is added they become active again. 
Hence, dried drugs must be protected from moisture during storage 
(Samuelsson, 1999; Morelli, 1981).  
Freeze-drying 
Freeze-drying (lyophilization) is a very mild method, useful for drying material 
containing heat-sensitive substances. Frozen material is placed in an 
evacuated apparatus which has a cold surface maintained at -40ºC to -80ºC. 
Water vapour from the frozen material passes rapidly to the cold surface. The 
method requires a relatively complicated apparatus and is much more 
expensive than hot-air drying (Samuelsson, 1999). 
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Freezing 
Freezing is another method of preservation of drugs which slows both decay 
of organic material and micro-organisms growth. In addition to the effect of 
lower temperatures on reaction rates, freezing makes water less available for 
bacterial growth and slows the enzymatic activity considerably. But the 
enzymatic activity is not completely inhibited, since lipase and invertase work 
until temperatures of -20ºC to -25ºC. However, this method is not very 
common for preservation of medicinal plants (Morelli, 1981). 
Influence of temperature 
As abovementioned temperature has to be controlled accurately when the 
compounds of interest in the plant material to be dried are heat-sensitive. 
Several compounds with pharmacological properties in Echinacea have been 
reported to be heat sensitive. Decreased concentrations of cichoric acid in all 
plant sections have been observed with increasing drying temperature from 
40ºC to 70ºC (Stuart and Wills, 2003). The loss of echinacoside in freeze-
dried roots compared with roots dried at 30ºC was 28%, and 45% when they 
were dried at 60ºC (Kabganian, 2002).  
Chemical degradation 
Chemical compounds can be lost through volatilization or chemical 
degradation. Volatile components can be lost from a sample by application of 
heat. Organic compounds degradation can occur in several ways: as 
biological, enzymatic, hydrolytic, chemical, photochemical, and thermal 
decomposition. 
Biological decomposition is due to the activity of microrganisms, like bacteria 
and fungi. This kind of decomposition can be excluded in correctly stored 
plant material. Both storage methods, drying and freezing, impede microbial 
growth severely. 
Enzymatic decomposition, as the name suggests is due to the activity of 
enzymes. Enzymes catalyze chemical reactions by lowering the activation 
energy, and therefore dramatically accelerating the reaction rate. The 
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majority of enzyme reaction rates are millions of times higher than those of 
comparable uncatalyzed reactions. In the absence of water enzymes show 
no, or a very low, activity, so dried plant material is not decomposed by 
enzymes during storage. In the case of frozen plant material enzymatic 
activity is very slow and alterations due to it are minimized, but we cannot 
completely exclude that some degradation occurs since some enzymes 
retain a certain degree of activity (even if very slow) till -20ºC - -25ºC (Morelli, 
1981). 
Hydrolitic degradation. Many compounds of interest in plant extracts are 
esters or glycosides and can therefore undergo hydrolysis reactions if 
experimental conditions are not carefully controlled. CADs are esters or 
glycosides of phenolic compounds (Baugh and Ignelzi, 2001).  
Chemical decomposition is due to oxidation by air oxygen. 1,2-diphenols 
(hydrochinones), like CADs can be easily oxidised to compounds containing 
two carbonilic groups (quinones). Phenolics are stabilized against oxidation 
in acidic solution (Baugh and Ignelzi, 2001).  
Photochemical decomposition is caused by exposition to UV-Vis radiation. 
The absorption of light initiates the reaction, placing the reactant molecules 
into an excited state. The reaction may then proceed with or without 
continuous irradiation. In a study on wines conservation it has been seen, 
that UV–Vis radiation influences the content of polyphenolic compounds 
(Benitez et al., 2006).  
Thermal decomposition (or thermolysis), is a reaction that occurs when a 
chemical substance is heated. At the decomposition temperature the 
substance breaks up into at least two chemical substances. The reaction is 
usually endothermic as heat is required to break chemical bonds in the 
compound undergoing decomposition. Decomposition temperatures for 
cinnamic acids are above 150ºC: for example 228ºC for cinnamic acid 
(https://fscimage.fishersci.com/msds/53351.htm), 176ºC for ferulic acid 
(Taniguchi et al., 2004). 
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Extraction methods 
The active principles of medicinal herbs can be obtained by different 
extraction methods, solvent extraction (solid-liquid separation) or more 
innovative techniques like supercritical fluid extraction (SFE).  
The solvent employed in the solid-liquid separation is chosen depending on 
the starting material and the compound of interest. If the active principle is 
located inside the plant cell, it’s necessary to render the cell membrane 
permeable to it or to disrupt the integrity of the cell membrane by acid 
solvents, by heat, or by osmotic pressure. Also mechanical operations can 
contribute to obtain better extraction efficiency, for that it’s recommended to 
grind the material to powder of suitable particle size as a first operation to 
perform. Well grinding is always helpful, even when the active principles are 
located in the intercellular space (Morelli, 1981). 
Different extraction methods produce differences in the chemical composition 
of the extract. It has been seen for example, that extracts from E. angustifolia 
roots have different characteristics if made by supercritical fluid extraction 
(SFE) or by traditional extraction, the latter was reported to give extracts 
which resulted richer in antioxidant metabolites than SFE extracts (Ferracane 
et al., 2007). 
The different extraction methods can be optimized when combined with 
techniques like ultra sonication (US), which may speed up and simplify 
sample treatment. Ultrasonic energy, when imparted to solutions, causes 
acoustic cavitation, that is, bubble formation and subsequent implosion. The 
collapse of bubbles created by the sonication of solutions results in the 
generation of extremely high local temperature and pressure gradients, which 
may be regarded as localized ‘‘hot spots.’’ On a timescale of about 10-10 s, 
effective local pressures and energies of about 105 atm and about 1 eV, 
respectively, are generated (Suslick, 1988). These localized high-energy 
environments formed by the application of ultrasound to solutions can be 
employed for the purpose of extracting analytes from their matrices, so that 
the species of interest may then be measured by instrumental techniques 
(Luque de Castro and da Silva, 1997; Ashley, 1998). 
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A short summary of the most common extraction methods is reported in 
Table 2. 
The extraction process is influenced by different factors. Active compounds 
are usually contained inside the cells. Some cells are broken during grinding 
and at contact with the solvent active compounds can diffuse directly in the 
surrounding liquid. Active principles inside intact cells are dissolved by the 
solvent that diffuses into the cell and comes in contact with the surrounding 
solvent after passing the cell wall. This process continues until the 
equilibrium is reached. The speed with which the equilibrium is reached 
depends on temperature, pH, particle size and the movement of the solvent, 
which facilitates the diffusion of the solvent and the diffusion trough the cell 
walls.  
A good solvent is selective, but not even too selective, especially for 
extraction of plants which active compounds aren’t well known. Certainly a 
solvent has to have a high capacity for extraction and should not react with 
the extracted compounds. It should have a low price, be harmless to man 
and environment and be completely volatile. Aliphatic alcohols with maximum 
tree carbon atoms have the greatest extractive power for almost all 
substances of low molecular weight. These alcohols are usually mixed with 
water to induce swelling of the plant particles and increase porosity of the cell 
walls which facilitates the diffusion of extracted substances. 
High temperatures reduce the extraction time. Further as abovementioned 
heat can help to disrupt the integrity of the cell membrane and inhibit enzyme 
activity (Morelli, 1981). In any case it’s important to control temperature when 
medicinal plant material contains heat-sensitive compounds.  
Each working step has to be carefully controlled. Grinding produces a certain 
amount of heat, for this reason mills cooled with liquid nitrogen are available.  
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Maceration 
This is the simplest procedure for obtaining an extract. It can be 
performed at room temperature by mixing the ground drug with the 
solvent and leaving the mixture for several days with occasional shaking 
or stirring (simple maceration) or by stirring the mixture continuously, 
usually overnight (kinetic maceration). The extract is then separated from 
the plant particles by straining and the procedure is repeated once or 
twice with fresh solvent. Maceration does not result in complete 
extraction of the desired compounds. Despite careful pressing of the 
residual plant material a certain amount of solute cannot be recovered 
(Samuelsson, 1999). Similar methods above room temperature are: 
digestion (extraction at moderate heat 35ºC to 65ºC), infusion (boiling 
water is poured over the plant material and left until room temperature is 
reached), decoction (the plant material is left at contact with the boiling 
solvent for up to 30 minutes or more). The choice between these 
extraction methods must be in respect of the chemical resistance to 
temperature of the compound of interest. 
 
Percolation 
In this procedure the plant material is packed in a tube-like percolator 
which is fitted with a filter sieve at the bottom. Fresh solvent is fed from 
the top until the extract recovered at the bottom of the tube does not 
contain any solute. This process is slow and costly, and it requires a 
large amount of fresh solvent. A technical problem in the percolation is to 
ensure an equal flow of solvent trough the drug material which for this 
reason should not be too finely ground (Samuelsson, 1999). 
 
Counter-current extraction 
This procedure is suitable for industrial scale. There are different types of 
extractors; in all of them, plant material moves against the solvent 
(Samuelsson, 1999). 
 
Table 2. Short description of the most common extraction methods for 
medicinal plant material. 
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Cont. 
 
Extraction with supercritical fluids 
Gases at temperatures and pressures above the critical point are called 
supercritical fluids or supercritical gases. Their physical properties 
(dielectric constant, density, diffusion coefficient, surface tension which is 
absent) are altered and make them potentially useful for extraction and 
chromatography. It is quite widespread in food industry (Samuelsson, 
1999). 
 
Solid phase micro-extraction (SPME) 
SPME requires two extraction steps. In a first step, a fiber, coated with 
an absorbent or stationary liquid, is exposed to a liquid sample and the 
analytes are absorbed to the fiber. In a second step the analytes are 
released in the injection chamber of a gas chromatograph or a liquid 
chromatograph. Because of the easier handling this method is used 
prevalently for gas chromatography. It has the advantage to be fast, high 
sensitive, generally applicable and to have low costs. 
Microwave assisted extraction (MAE) 
MAE is carried out at a temperature between 150ºC and 190ºC, 
therefore it’s suitable only for thermally stable analytes. MAE is based on 
the absorption of microwave energy by molecules of polar chemical 
compounds. The extraction efficiency depends on the solvent properties, 
sample material and the dielectric constants of the components to be 
extracted, since the energy absorbed is proportional to the dielectric 
constant of the medium. This method has the advantage to shorten 
extraction time, to reduce the amount of solvent used and to permit an 
easy control of sample heating (Romanik, 2007). 
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2. EXPERIMENTS 
2.1 INTRODUCTION 
General and specific objectives 
Chemical standardisation of medical plant material is a central point in 
production of herbal medicines. In order to get a better standardisation for 
Echinacea preparations, alkamides and phenolic compounds, as suggested 
by Bauer (1999a), are commonly used as marker compounds (Bauer et al., 
1988). Marker compounds have the function to provide information for the 
quality control of standardized products. Several Echinacea preparations 
commercialized on the international market have been reported to contain 
different amounts of constituents, believed to be responsible for the 
pharmacological activity, than indicated on their labels (Mølgaard et al., 
2003). It can be interpreted that manufactures sometimes use raw material of 
poor quality in their products, that the products have a low stability, and that 
there is a high variability between production batches. The latter problem in 
particular, which is closer to the production process, has emerged also in our 
laboratory. The variability of active components between four production 
batches, cultivated in a greenhouse hydroponic system, resulted very high 
even if growth conditions had been uniformed as much as possible (Figure 2; 
Tozzini, 2006). One possible reason is the inaccuracy of the whole sample 
processing (storage, pre-extraction treatment, extraction and quantitative 
analysis). 
In order to investigate the occurrence of possible bias due the method used 
to process and analyze plant samples, we conducted several laboratory 
experiments either on roots and on leaves of E. angustifolia and used several 
CADs as reference compounds. During extraction the plant material 
undergoes different conditions which could influence the composition in 
active principles. Therefore, a work was undertaken i) to elucidate the effect 
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of different treatments of plant samples before extraction and HPLC analysis, 
ii) to verify and possibly improve the extraction protocol; iii) to quantify the 
loss of active principles during extraction and analysis of plant extracts.  
 
 
Figure 2. Contents of echinacoside in vegetative root and leaf tissue among 
four production batches. A high inter sample variability is recognizable. 
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2.2 MATERIALS AND METHODS  
Plant material 
Plants were grown in a hydroponic floating raft system. The capacity of the 
plastic tanks used was 65 L, with a ratio volume/surface of circa 280 L m-2. 
The nutritive solution (macro- and microelements) was adjusted to pH 6.0, 
and electrical conductivity of 2.7 dS m-1. The hydroponic system was aerated 
and the oxygen content in the nutrient solution was 5-6 mg L-1.  
In each tank 40 plants were grown after they were planted on a polistirene 
tray. Plants were transferred to this system 30 days from sowing and were 
harvested 16 weeks from sowing. 
Nutritive solutions and stock solutions were prepared with ground water and 
were completely substituted every 30 days. The concentrations of the 
macroelements are reported in Table 3. Further, 0.8 g of a micronutrient 
mixture, Mix 5 SG (Valagro SpA, Chieti, Italy) and 0.8 g iron (chelated) were 
added to each tank. 
 
 
A total of fifteen hydroponically-grown plants were harvested in July 2007. 
Each plant was separated into roots and leaves. Damaged, yellow and dry 
leaves were removed and petioles were cut away with scissors. Leaves of 
the different plants were mixed together, immersed one by one for a few 
seconds in distilled water, and placed on absorbent paper. A second layer of 
absorbent paper was placed on the washed leaves and a light pressure was 
exerted with the hands. Leaves were then transferred on another dry 
absorbent paper for complete drying. Samples were prepared in little paper 
bags for drying and in aluminium foils for freezing. 
Table 3. Concentration of macroelements in the nutritive solution used for 
growing the E. angustifolia plants in the hydroponic system. 
Elements N P K Mg Ca SO4 Na 
Concentration 8 1 5 2 4 2 8 
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Roots were stored after harvesting in the refrigerator at 4ºC for about 1 hour. 
Rotten root parts were removed. Roots were washed and dried as previously 
described for leaves, then they were cut in small pieces and mixed together; 
finally the paper bags or aluminium foils for sample storage were prepared.  
Roots were also sampled in a different way, eliminating the secondary roots, 
in order to collect homogeneous plant material. In this case roots were 
immersed for a few seconds in water containing sodium hypochlorite and 
rinsed with mineral water.  
 
 
 
Samples were frozen at -80ºC and -20ºC, or dried at 25ºC (room 
temperature), 50ºC and 75ºC in ventilated oven until the dry weight became 
stable. Then they all were stored at room temperature in capped tubes.  
Chemicals 
Pure HPLC standard compounds: echinacoside, cynarine, cichoric acid, and 
caftaric acid were purchased from Phytolab GmbH & Co. KG 
(Vestenbergsgreuth, Germany), while chlorogenic acid, caffeic acid, ferulic 
Echinacea angustifolia plants cultivated in hydroponic system after 
9 weeks from sowing. 
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acid, and p-cumaric acid were purchased from Sigma-Aldrich (Milano, Italy). 
Hydrochloric acid (37%), orthophosphoric acid (85%) and HPLC grade pure 
solvents (water, methanol, acetonotrile, and ethanol) were all purchased form 
Carlo Erba Reagenti SpA (Rodano, Italy). 
HPLC determinations 
Standard preparation 
The standards were prepared by weighting the solid substances with an 
accurate scale Handy H110 analytical balance (Sartorius, Goettingen, 
Germany). Because the quantity of weighted material was very little (about 2 
mg) the concentration of every standard solution prepared was confirmed via 
spectrophotometric determination by registration of the UV-Vis spectra and 
comparison with analogous spectra obtained from solutions with a known 
concentration used in previous works. Stock solutions were obtained by 
dissolving the carefully weighted solid in 10 mL MeOH/aqueous solution of 
0.1% H3PO4 (70:30, v/v). Appropriate aliquots of these solutions were diluted 
to a total volume of 10 mL with methanol in the way that the maximum 
absorbance would be about 0.8 (Table 4). Spectra of each standard were 
recorded in the range 200 nm - 500 nm by a  Lambda 35 UV-Vis  double 
beam spectrophotometer (Perkin Elmer, Beaconfield, England), using pure 
methanol as reference solution. 
 Compound Concentration (ppm) 
Echinacoside 40  
Caffeic acid 21  
Clorogenic acid 29  
Cinarin 13.6  
Ferulic acid 11.0  
Cichoric acid 20.0  
Paracumaric acid 4.8  
Caftaric acid 13.5  
Table 4. Standard concentrations of the different CADs for UV-Vis spectra 
registration. 
 32 
Calibration 
Calibration curves were realized by interpolation of three experimental points 
(two points in the case of echinacoside, cynarine and cichoric acid). Further, 
the agreement of the calibration curves with analogous standard curves 
registered in previous experiments was verified for major confidence. 
Analysis  
For high performance liquid chromatography analysis a liquid 
chromatography apparatus (Jasco, Tokyo, Japan) was used, equipped with a 
low pressure quaternary pump (mod. PU-2089) and a UV/Vis multichannel 
detector (mod. UV-2077). Analysis were carried out with a Macherey-Nagel 
C18 250/4.6 Nucleosil® 100-5 column, at a flow rate of 1 mL min-1, using as 
elution solvents acetronitrile (solvent A) and a water solution containing 0.1% 
o-phosphoric acid (solvent B) with the following gradient: 0.0-0.4 min, B 95%; 
0.4-0.5 min, B 95-85%; 0.5-10 min, B 85-80%; 10-20 min, B 80-60%; 20-21 
min, B 60-5%; 21-25 min, B 5%; 25-26 min, B 5-95%; 26-30 min, B 95%. 
Detection was made at four wavelengths: 325 nm, 280 nm, 300 nm, and 350 
nm. The injection volume was 20 µL, and the analysis where made at room 
temperature (20°C-25°C). All extracts were filtered with Chromafil®  0.45 µm 
cellulose mixed esters membrane, 25 mm diameter syringe filters, 
(Macherey-Nagel, Düren, Germany) prior to HPLC separations.  
CADs were identified on the basis of the retention time of the external 
standard and quantified per peak integration on the basis of the respective 
calibration curves. For each temperature, four replicates were extracted and 
analyzed.. 
Sample preparation and extraction: protocol 1 
Oven dried plant material  
The dry samples were kept one night in a desiccator before grinding. Dry 
plant material was ground in a porcelain mortar and sieved into plastic tubes. 
Each sample was constituted of about 0.2 g dry powdered tissue and was 
added of 5.0 mL extraction solvent (MeOH/H2O 70:30, v/v) under a fume 
hood. The tubes were stored overnight at -20ºC, then they were well shaken 
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by hand, and placed on a magnetic stirrer for four hours (or alternatively 
placed on the orbital shaker for four hours). The tubes were centrifuged for 
two min at 2700 g. The supernatant liquid was collected in new plastic tubes 
and stored at -20ºC. Other 5.0 mL extraction solvent was added to the pellet 
and the extraction procedure was repeated. Finally, the two supernatant 
aliquots were combined and stored at -20ºC.  
Frozen plant material  
Frozen plant material stored at -20°C or -80°C was ground in a porcelain 
mortar with the help of liquid nitrogen and sieved into plastic tubes. The 
equipment used for tissue handling (mortar, plastic funnel and tube, sieve, 
spatula) had previously been frozen with liquid nitrogen. Each sample was 
constituted of roughly 0.5 or 1.0 g homogenized tissue. The extraction was 
carried out as described in the previous paragraph, using in total 10.0 mL or 
5.0 mL extraction solvent for 1.0 g or 0.5 g samples, respectively.  
Lyophilized plant material 
Samples were stored at -80ºC for three months. For lyophilization each 
sample was placed in a plastic box covered with perforated Parafilm®. The 
samples were kept cold with ice during handling and placed in the already 
cooled freeze drier (Mini-fast mod. 1700, Edwards, Milano, Italy). 
Lyophilization was carried out at -40ºC and at a pressure of 10-1 torr for 48 
hours. Freeze dried samples were kept one hour in a desiccator and handled 
like the other dry samples.  
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Loss determination 
Use of internal standard 
In order to quantify the loss of active principles, the sample were added with 
a known amount of internal standard, which was gallic acid. Gallic acid 
solutions at 2.0% and 0.8% were prepared with MeOH/H2O (70:30, v/v) and 
50 µL of these solutions were added to the sample just before the addition of 
5.0 mL extraction solvent (MeOH/H2O, 70:30 v/v, or MeOH/H2O/HCl, 70:29:1 
v/v). In this way a final concentration of 99.5 ppm or 39.8 ppm gallic acid was 
reached in the different samples. After homogenization, the whole content 
was transferred to a plastic tube and the extraction was carried out as usual. 
For this trial lyophilized roots and roots frozen at -80ºC were used. The 
extraction was held out under the fume hood. 
Standard addition 
In order to determine the occurrence of a matrix effect, which may reduce or 
increase the determined concentration of metabolites, a solution of cynarin in 
the extraction solvent (MeOH/H2O, 70:30 v/v, or MeOH/H2O/HCl, 70:29:1 
v/v). with a concentration of 100 ppm was prepared. Samples of freeze dried 
plant material were prepared as aforementioned with a final concentration of 
gallic acid of 99.5 ppm. 10 or 20 ppm cynarin were added before injection. 
Cynarin concentration was registered before and after standard addition.  
Statistical analysis 
Treatment effects were subjected to analysis of variance. The significance of 
the differences among mean (n = 4) values  were tested by Tukey’s test. 
Internal standard means were compared by unpaired, two-tailed t-test. 
Statistical analysis was conducted using GraphPad Prism® 4.0, Graph Pad 
Software Inc., San Diego, CA, USA. 
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2.3 RESULTS AND DISCUSSION 
Influence of drying and storage temperature  
Roots and leaves dried at 75ºC and at 50ºC required 6 days to reach 
constant dry weight, while at 25ºC it took 27 days. Methanol/water (70:30, 
v/v) was used as the extraction solvent, since it had shown a good efficiency 
in similar extraction experiments (Ferracane et al., 2007). The determination 
of CADs content was made by means of eight standards, but only five 
metabolites where revealed in significant amount in root and leaf tissue: 
caftaric acid, echinacoside, chlorogenic acid, cynarin, cichoric acid. Caffeic 
acid, p-coumaric acid, and ferulic acid often were not detected or were 
present at concentrations under the detection limit of the HPLC method, 50 
µg g-1 dry weight (DW). Furthermore, there was no chlorogenic acid detected 
in leaf tissue, while caftaric acid was absent in roots.  
It was evident in this first experiment, that root tissue has a higher CADs 
content than leaf tissue (Figure 3 and Figure 4), as showed also in other 
studies (Kabganian et al., 2002). The highest concentrations in roots were 
2.9 mg g-1 DW for cynarin and 1.6 mg g-1 DW for echinacoside, while in the 
leaves the highest concentrations observed were 0.8 mg g-1 DW for cynarin  
and 0.9 mg g-1 DW for echinacoside. 
Dried roots 
In dried root material no common trend could be seen among the four main 
metabolites for the different drying temperatures. Contents of chlorogenic 
acid increased with increasing drying temperature. The highest cynarin 
content was found at drying temperature of 25°C, while there was no 
difference between contents revealed at 50°C and 75°C. Echinacoside 
content resulted lower at 25°C compared to the other temperatures. The 
behaviour of the echinacoside concentration is in contrast with observations 
made in another study, where the content decreased with increasing 
temperatures and showed significant differences between drying 
temperatures (Kabganian et al., 2002). The highest content of cichoric acid 
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was found in tissue dried at 50°C and the lowest one in tissue dried at 25°C. 
Tissue dried at 50°C showed the highest total metabolite content, while 
tissue dried at 25°C showed the lowest one (Figure 3).  
In this experiment, data obtained from entire roots (main root plus hairy roots) 
were also compared to data obtained using only main root material. 
Generally there were no differences between the two different tissues apart 
from cichoric acid at 50ºC which was present in higher concentration when 
also hairy roots were present, in agreement with what reported in the 
literature (Letchamo et al., 2002), and chlorogenic acid at 25ºC which was 
contained in higher amount in the main root. 
Dried leaves 
Leaf tissue showed no difference for single metabolites content at the drying 
temperatures of 50°C and 75°C. Tissue dried at 25°C gave the lowest 
contents for the single metabolites, which were not significantly differnet from 
the ones found in tissue dried at 75°C in the case of cynarin and 
echinacoside, and tissue dried at 50°C in the case of caftaric acid. Chicoric 
acid was under the detection limit at 25°C. The total metabolites content was 
similar at the drying temperatures of 50°C and 75°C, while it was lower for 
leaves dried at 25°C (Figure 4).  
 
 37 
 
0
500
1000
1500
2000
2500
3000
3500
c
b
a
25°C
50°C
75°C
C
h
lo
ro
g
e
n
ic
 a
c
id
 (
µµ µµ
g
 g
-1
D
W
)
 0
500
1000
1500
2000
2500
3000
3500
a
b
b
C
y
n
a
ri
n
(( ((µµ µµ
g
 g
-1
D
W
)
 
0
500
1000
1500
2000
2500
3000
3500
b
a
a
E
c
h
in
a
c
o
s
id
e
(( (( µµ µµ
g
 g
-1
D
W
)
 0
500
1000
1500
2000
2500
3000
3500
c
a
b
C
ic
h
o
ri
c
 a
c
id
 (
µ
 (
µ
 (
µ
 (
µ
g
 g
-1
D
W
)) ))
 
Figure 3. Chlorogenic acid, 
cynarin, echinacoside, chicoric 
acid and total content 
concentrations (µg g-1 dry weight) 
of Echinacea angustifolia roots 
under different post harvest 
treatments, roots dried at 25°C, 
50°C, and 75°C respectively. 
Results are expressed as means 
(colums) and standard errors. Bars 
bearing the same letter are not 
different (P<0.05) according to 
Tukey’s Test after one-way 
ANOVA for each metabolite, (n=4). 
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Figure 4. Caftaric acid, cynarin, 
echinacoside, chicoric acid and 
total content concentrations (µg g-
1 dry weight) of Echinacea 
angustifolia leaves under different 
post harvest treatments, roots 
dried at 25°C, 50°C, and 75°C 
respectively. Results are 
expressed as means (colums) and 
standard errors. Bars bearing the 
same letter are not different 
(P<0.05) according to Tukey’s Test 
after one-way ANOVA for each 
metabolite, (n=4), *= not 
detectable. 
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Frozen and freeze dried plant material 
Frozen and freeze dried plant tissue contents were compared to plant 
material dried at 50°C, since this postharvest treatment gave the best results 
in terms of total metabolites content and because plant material is commonly 
dried at similar temperatures in herbal medicine industries. 
Freeze dried or frozen (-20°C and -80°C) root material revealed much lower 
CADs content compared to tissues dried at 50°C. Conversely, leaf tissuedid 
not show such evident differences among the treatments (Figure 5 and 
Figure 6). 
 Each metabolite was present in freeze dried and frozen roots in 
concentractions lower than 500 µg g-1 DW. Chlorogenic acid in root samples 
frozen at -80°C and cynarin, echinacoside, and chicoric acid in samples 
frozen at -20°C were below the detection limit. Chicoric acid content was 
detected in higher amount in freeze dried than in frozen (-80°C) root tissue, 
while echinacoside contentwas similar for the two treatments. Chlorogenic 
acid and cynarin contents were lower in freeze dried root tissue than in roots 
frozen at –20°C and –80°C respectively. The total content of the four 
metabolites was similar in frozen and freeze dried material, while it resulted 
much lower in dried roots (Figure 5). 
As already mentioned the detected metabolites contents in leaves were 
relatively low, but only caftaric acid for freeze dried leaves resulted below the 
detection limit. Generally individual metabolites were present in similar 
amounts in samples deriving from the different treatments. However, there 
were some exceptions: frozen (-20°C) tissue had the lowest cynarin content, 
freeze dried tissue showed the highest echinacoside content, while the 
content of cichoric acid was higher in freeze dried material than in tissue 
frozen at –20°C or dried tissue. The total content of the four metabolites was 
similar for the different treatments, except for frozen tissue (–20°C), where it 
resulted lower (Figure 6). 
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Figure 5 Chlorogenic acid, 
cynarin, echinacoside, chicoric 
acid and total content 
concentrations (µg g-1 dry weight) 
of Echinacea angustifolia roots 
under different post harvest 
treatments, freezed at –20°C and –
80°C, freeze dried and dried at 
50°C respectively.Results are 
expressed as means (colums) and 
standard errors. Bars bearing the 
same letter are not different 
(P<0.05) according to Tukey’s Test 
after one-way ANOVA for each 
metabolite, (n=4), *= not 
detectable. 
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Figure 6 Chlorogenic acid, cynarin, 
echinacoside, chicoric acid and total 
content concentrations (µg g-1 dry 
weight) of Echinacea angustifolia 
leaves under different post harvest 
treatments, freezed at –20°C and –
80°C, freeze dried and dried at 50°C 
respectively.Results are expressed 
as means (colums) and standard 
errors. Bars bearing the same letter 
are not different (P<0.05) according 
to Tukey’s Test after one-way 
ANOVA for each metabolite, (n=4), 
*= not detectable. 
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Extraction improvement in frozen and freeze dried samples 
In contrast with leaf samples, which gave relatively homogenous results 
among the different drying and freezing temperatures, the behaviour of 
frozen roots samples was not excpected, since their CADs contents were 
very low compared to the oven dried root material.. Even lyophilization, a 
very mild drying process, had not shown higher CAD contents in frozen root 
material. This behaviour of root tissue interested us, because of the lack of 
information about this concern in the literature and also because of the 
importance of Echinacea angustifolia root tissue, which has higher CADs 
contents than leaf tissue.  
The hypothesis, that CADs might be bound to the cell wall or other cell 
structures and could be released only with the influence of elevated 
temperatures, didn’t appear convincing because of the relatively mild 
temperatures applied to plant material during oven drying.  
Anyway, it was apparent that the extraction method did not fit for frozen root 
tissue. For this reason several trials with the goal of extraction optimisation 
and loss evaluation were carried out.  
Extraction with ultrasonic or glass homogenizer 
These experiments were a first attempt to improve the CADs extraction in 
frozen roots.  
In the first extraction trial magnetic stirring step was replaced by 30 minutes 
sonication with ultrasonic homogenizer Starsonic 60 (Pbi International, 
Milano, Italy) at room temperature and 50ºC. Root samples were compared 
for CADs contents with the respective controls, extracted according to the 
former protocol (protocol 1) at room temperature and 50ºC respectively.  
The second trial consisted in modifying only the grinding step in protocol 1: 
mortar and pestle were replaced by a glass potter in order to obtain a better 
homogenization of root material.  
Since neither the sonication method or the use of the glass potter gave better 
results compared to the former extraction protocol (protocol 1) it was decided 
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to abandon the extraction with ultrasonic homogenizer or glass homogenizer 
to concentrate on more promising methods. 
Modification of the extraction protocol: protocol 2 
In order to obtain a higher CADs content from frozen roots at -80°C, the 
extraction solvent was added to the sample prior to tissue grinding (protocol 
2).  
Protocol 2 showed a higher metabolites extraction efficiency than protocol 1 
and was adopted for subsequent extractions. The addition of the extraction 
solvent to the tissue before grinding limits the contact with air oxygen which 
may have a preserving action on the CADs (Nüsslein et al., 2000).  
Modification of the extraction protocol: protocol 2+HCl 
Presumably CADs are degraded during handling and extraction in frozen and 
freeze dried material. It was suspected that the loss could be due to the 
activity of enzymes during handling and extraction, since some CADs have 
been reported to be susceptible to enzymatic degradation and oxidation in 
alcoholic extraction (Wölkart et al., 2004). Polyphenol oxidase (PPO), has 
been reported to be the most important enzyme in degradation of CADs 
(Nüsslein et al., 2000; Wölkart et al., 2004). This enzyme catalyzes two 
different reactions, the hydroxylation of monophenols to o-diphenols and the 
oxidation of o-diphenols to o-diquinones (Martinez and Whithaker, 1995). The 
latter reaction is responsible for the loss of CADs (Figure 7). Since most 
plants show maximum PPO activity at or near neutral pH values (Dogan, 
2004), denaturation by extremely low pH values (Scopes, 1987) was chosen 
for inactivation. 
 
 
Figure 7. Oxidation of an o-diphenol (1) to o-diquinone (4) and its 
intermediary steps, a reaction catalyzed by polyphenol oxidase. 
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Extractions were made applying protocol 2 with the use of acidified solvent, 
MeOH/H2O/HCl (70:29:1, v/v) (protocol 2+HCl). Solvents pH values were 
measured after extraction. In protocol 2 pH values ranged from 6.2 to 6.9, 
while in protocol 2+HCl pH values ranged from 0.6 to 0.7. 
From the comparison of the concentration of CADs detected with protocol 1 
and protocol 2, a certain amelioration of the extraction for all treatments 
(roots dried at 50°C, frozen at -80°C and freeze dried roots) was observed. 
Tissue stored at –80°C showed an increment in the content of chlorogenic 
acid and echinacoside. Freeze dried tissue showed an increment for 
echinacoside and cynarin, while in the case of dried plant tissue only the 
chlorogenic acid content increased. Even better results gave protocol 2 with 
acidified solvent (protocol 2+HCl). Frozen (-80°C) roots showed an increment 
of content for all metabolites when extracted with protocol 2+HCl compared 
to protocol 2. Freeze dried tissue showed only an increment for chlorogenic 
acid, while in the case of dried plant tissue the echinacoside and cynarin 
content increased. 
The total metabolites content for the different protocols was the highest one 
for all treatments when protocol 2+HCl was applied. Protocol 2 compared to 
protocol 1 showed higher total content for freeze dried and frozen roots, but 
didn’t show different contents for dried roots. 
In conclusion protocol 2 gave better results for frozen and freeze dried root 
tissue than protocol 1. With protocol 2+HCl compared to the other protocols 
the highest total metabolite contents were detected (Figure 8). 
Also root material frozen at -20ºC was analyzed. Registered metabolite 
contents were very low and often not detectable. Therefore no increment in 
CADs content with protocol 2, and even with protocol 2+HCl, was obtained. 
This result is probably due to incorrect storage, because the root material 
was browned and CADs had probably undergone an oxidation process 
before handling and extraction. 
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Figure 8. Chlorogenic acid, cynarin, echinacoside, chicoric acid and total 
content concentrations (µg g-1 dry weight) of Echinacea angustifolia roots for 
three different extraction protocols (protocol 1, protocol 2, and protocol 
2+HCl). Root material derived from different post harvest treatments, freezed 
–80°C, freeze dried, and dried at 50°C respectively.Results are expressed as 
means (colums) and standard errors. Bars bearing the same letter are not 
different (P<0.05) according to Tukey’s Test after one-way ANOVA for each 
metabolite, (n=4), *= not detectable. 
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Loss determination 
Use of internal standard  
Internal standards are used for the evaluation of possible losses and 
degradation of the compounds of interest during the extraction process. An 
internal standard is a compound with chemically similar properties to the 
compounds of our interest but which is not present in the plant material. A 
carefully measured amount of an internal standard is added to each sample 
and undergoes from this moment the same extracting conditions like the 
compounds of interest. The peak area (or height) of the internal standard is 
then correlated to the calibration curve of the internal standard for 
quantification of the losses (Skoog et al., 1991).  
Gallic acid was chosen as internal standard in our analyses because it is 
absent in E. angustifolia tissue, but its chemical structure is similar to other 
Echinacea CAD’s. Further gallic acid has a relatively close but well separated 
peak from the peaks of all other components detected in the sample. 
The results obtained with protocol 1 for both, freeze dried and frozen root 
tissue, showed very high losses of internal standard, ranging from 84% to 
95%. In case of samples extracted with the protocol 2, there were no 
important losses of gallic acid, with the exception of root samples frozen at -
80°C (loss of 23 %). When extraction was made with protocol 2+HCl no 
losses were detected, even in samples frozen at -80°C. This result is in 
agreement with the total metabolite content observed for frozen material, 
where a significant amelioration of extraction efficacy was observed when 
root tissues were extracted with protocol 2+HCl compared to protocol 2. An 
example of a registered chromatogram obtained with protocol 2+HCl is 
shown in Figure 9. 
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Figure 9. Chromatogram registered at 325 nm of a frozen (-80°C) root 
sample extracted with protocol 2+HCl and with addition of internal standard. 
Standard addition  
For a major accuracy of data obtained it’s important to know whether there 
are or not interferences with the analytical method. To establish the method 
reliability, the standard addition method is a useful tool. Calibration standards 
should approximate the composition of the samples to be analyzed not only 
in respect of the analyte concentration, but also of the concentration of the 
other species in the sample matrix, in order to minimize the effects of various 
components of the sample on the measured peak area. The common method 
for standard addition involves adding one or more increments of a standard 
solution to sample aliquots of the same size. Measurements are made on the 
original and after each addition. The effectiveness of the method is then 
evaluated by the extent of recovery of the added quantity. When the 
measured concentration is lower than the calculated one, we are in presence 
of an error arisen from the way the sample was treated or from the presence 
of the other elements or compounds in the matrix (Skoog et al., 1991). 
Cynarin was chosen for standard addition because of its importance as 
marker compound. It was added to samples extracted following both protocol 
2 and protocol 2+HCl. The obtained results showed that no losses of cynarin 
occurred in the plant tissue matrix; hence, a matrix effect has been excluded 
for cynarin. Since the other metabolites analyzed have similar chemical 
properties, it was assumed that they behave in the same way.  
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3. CONCLUSIONS 
The efficacy of the extraction method for CADs of plant tissue of Echinacea 
angustifolia was substantially ameliorated with this work. 
Preliminary experiments evidenced that for both root and leaf tissues, the 
drying temperature of 50°C gave better results, in terms of concentration of 
individual or total metabolites contents, than 25°C and 75°C. By contrast, the 
extraction efficacy was much lower for frozen and freeze-dried root samples 
compared to the ones desiccated at 50°C. Extraction efficacy of frozen and 
freeze dried root tissue was dramatically incremented by modifying the 
extraction protocol 1 by adding the extraction solvent before grinding 
(protocol 2). A further amelioration was obtained by acidifying the extraction 
solvent with HCl (protocol 2+HCl). This modification gave the best extraction 
results in all types of samples (frozen, freeze-dried, dried at 50°C). The 
highest increment was obtained for frozen (-80°C) root tissues, whose total 
content resulted 19 or 3 times higher than the values determined using the 
extraction protocol 1 or 2, respectively. 
The considerable increment for frozen tissue is probably due to the inhibition 
of enzymatic activity by extreme low pH values and minimized oxygen 
contact. Solvent acidification improved the extraction of 50°C-dried samples 
as well; indeed, the total content of selected metabolites increased by 40% 
with respect to protocol 2. Echinacoside content extracted with acidified 
solvent was about two times higher than with the other protocols.  
Notwithstanding the significant improvement of sample extraction, in plant 
samples analyzed in this work the content of echinacoside, the marker used 
for quality assessment, never exceeded the minimum value of 1% DW 
(10000 µg g-1 DW) and this was the case also for the Echinacea samples 
analyzed in previous work (Tozzini, 2006) after proper correction for the loss 
estimated in this study.  
The reasons for low content of caffeic acid derivatives in the root tissues of 
Echinacea plants grown hydroponically remain to be discovered. One may 
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speculate that the fast growth and the relatively short cultivation period (less 
than four months) hinder the massive accumulation of active principles that is 
generally observed in slowly-growing plants cultivated in soil, where they are 
typically harvested after three or four years (Aiello, 2002). 
 
 
 
 Inflorescenze of Echinacea angustifolia 
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5. SUMMARY 
The use of medicinal plants has increased considerably in the past two 
decades in industrialized countries. Three species of the genera Echinacea, 
belonging to the Compositae family, are among the top-selling plants of 
pharmacological interest. The species E. angustifolia, E. purpurea, and E. 
pallida are recognized for their immunostimulating properties and are used 
for their preventative actions, but also as remedies, so as to decrease the 
severity and duration of the symptoms of the common cold. The 
pharmacological action has been ascribed to several classes of compounds: 
alkylamides, glycoproteins, polysaccharides and caffeic acid derivatives. The 
latter class of compounds, deriving from the shikimate pathway, includes 
some important molecules for quality control in Echinacea, such as 
echinacoside and cynarin, which are the most common marker compounds 
mentioned by the literature and are largely adopted by the industry as well. 
Standardization of medical products is of primary importance in order to bring 
on the market products that are uniform in term of active principle contents 
between the different production batches, and that reflect chemically the 
information on the etiquettes. Currently, this condition is not fulfilled in many 
cases for several medical plants. Evidences from the literature and from 
previous work in our laboratory show an elevated variability in caffeic acid 
derivative contents among different production batches; such a variability 
may result from inadequate post-harvest processing and extraction of plant 
samples. Therefore, a work was undertaken i) to elucidate the effect of 
different treatment of plant samples before extraction and HPLC analysis, 
and ii) to verify and eventually improve the extraction protocol. In one of the 
first experiments, the attention was paid to the influence of the storage 
temperature and/or dehydration by oven drying or lyophilization on the 
content of caffeic acid derivatives in roots and leaves of Echinacea 
angustifolia plants grown hydroponically under greenhouse conditions. The 
main metabolites determined in plant tissues were echinacoside, cynarin, 
caftaric acid, chlorogenic acid and cichoric acid. Generally, the temperature 
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did not influence much the content of detected phenolics in oven dryed 
samples, while the level of these metabolites were very low or even under 
detection limit in fresh samples extracted after storage at freezing 
temperature or in the lyophilized ones. The relatively low temperatures used 
for sample drying exclude the hypothesis that, in fresh tissues, caffeic acid 
derivatives are bound to cellular components and that the drying process 
makes them available to analytical detection. More likely, a degradation of 
metabolites of interest occurs during the extraction process in fresh samples 
or during freeze drying. To verify the hypothesis of sample degradation, the 
extraction protocol was modified in a first step by adding the extraction 
solvent (methanol-water, 70:30) prior to tissue homogenization. In a second 
step the solvent was also acidifyied by hydrochloric acid 1%. Finally, using 
internal standard (by adding to the sample gallic acid, a compound not 
detected in Echinacea plant tissues) the loss of active principles was 
estimated. The extraction of caffeic acid derivatives was improved by 
modifying the extraction protocol and showed the best results in frozen and 
lyophilized roots by acidification of the solvent.  
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6. RIASSUNTO 
L’utilizzo di piante medicinali è incrementato considerevolmente negli ultimi 
vent’anni nei paesi industrializzati. Nel genere Echinacea troviamo tre specie, 
appartenenti alla famiglia delle Compostitae, che si collocano tra le piante più 
vendute di interesse farmacologico Le specie E. angustifolia, E. purpurea e 
E. pallida sono riconosciute per le loro proprietà immunostimolanti utilizzate 
in maniera preventiva, ma anche curativa, in quanto riducono gravità e 
durata dei sintomi del raffreddore. L’effetto farmacologico è stato ascritto a 
diverse classi di sostanze: agli alchilammidi, alle glicoproteine, ai 
polisaccaridi, e ai derivati dell’acido caffeico. Tra quest’ultimi composti, 
polifenolici derivati dalla via metabolica dello scichimato, si trovano importanti 
molecole comunemente adottate dall’industria e indicate in letteratura come 
marker di qualità dell’Echinacea, quali l’echinacoside e la cinarina. La 
standardizzazione dei prodotti per uso medicinale è di fondamentale 
importanza per poter immettere sul mercato un prodotto che presenti 
contenuti di principi attivi costanti tra i diversi lotti di produzione e che 
rispecchi chimicamente ciò che è riportato sull’etichetta. Allo stato attuale, 
per diversi medicinali vegetali questo requisito rappresenta ancora un 
problema. Evidenze trovate in letteratura e in un lavoro precedente eseguito 
nel nostro laboratorio mostrano una variabilità elevata nel contenuto dei 
derivati dell’acido caffeico riscontrata tra diversi lotti di produzione, 
presumibilmente in parte provocata dalla coltivazione in condizioni ambientali 
diverse, ma che potrebbe anche essere dovuta ad un trattamento post-
raccolta e un protocollo di estrazione non adeguato. Perciò è stato fatto il 
lavoro i) per chiarire l’effetto dei diversi trattamenti dei campioni vegetali 
prima dell’estrazione e l’analisi HPLC, e ii) per verificare e finalmente 
migliorare il protocollo di estrazione. In un primo approccio il lavoro si è 
concentrato sulla osservazione dell’effetto della temperatura di essiccazione 
o conservazione sul contenuto dei derivati dell’acido caffeico in radici e foglie 
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di piante di Echinacea angustifolia cresciute in un sistema d’idroponica in 
serra. 
I metaboliti principali determinati nel material vegetale sono: echinacoside, 
cinarina, acido caftarico, acido clorogenico e acido cicorico. Le diverse 
temperature di essiccazione in generale hanno influito poco sul contenuto 
rilevato dei composti fenolici, mentre per le radici congelate a diverse 
temperature i risultati hanno mostrato contenuti bassissimi o nulli di composti 
fenolici. L’ipotesi che i derivati dell’acido caffeico nel tessuto fresco siano 
legati ad altri componenti cellulari e che il processo di essiccazione li possa 
rendere disponibili in forma libera e rilevabile all’analisi cromatografica può 
essere escluso dal fatto che le temperature di essicazione sono 
relativamente basse. Più probabile è il verificarsi di una degradazione del 
materiale vegetale durante il processo di estrazione di campioni non 
dissidratati o liofilizzati. Per verificare la correttezza di questa ipotesi si è 
modificato il protocollo di estrazione e il solvente di estrazione 
(metanolo/acqua, 70:30) è stato aggiunto prima della macinazione. Il 
protocollo è stato modificato ulteriormente acidificando il solvente di 
estrazione con acido cloridrico all’1%. Inoltre è stata valutata la perdita di 
metaboliti durante il processo di estrazione mediante l’uso di uno standard 
interno (aggiungendo ai campioni acido gallico, un composto non rilevato nei 
tessuti di Echinacea). L’estrazione di derivati del acido caffeico è stata 
migliorata tramite le modifcazioni del protocollo. Il materiale congelato ha 
dato risulati migliori quando si usava il protocollo con il solvente acidificato. 
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7. ZUSAMMENFASSUNG 
Der Gebrauch von Heilpflanzen ist während den letzten zwei Jahrzehnten in 
den Industriestaaten beträchtlich angestiegen. Drei Arten der Gattung 
Echinacea, welche der Familie der Korbblütler angehört, finden sich unter 
den meistverkauften Pflanzen pharmakologischen Interessens. Die Arten E. 
angustifolia, E. purpurea und E. pallida sind für ihre immunstimulierende 
Wirkung bekannt und werden als vorbeugende Medizin, doch auch als 
Heilmittel, indem sie die Dauer und Schwere der Symptome von Erkältungen 
vermindern, eingesetzt. Die pharmakologische Wirkung wird verschiedenen 
chemischen Stoffklassen zugeschrieben: Alkylamiden, Glykoproteinen, 
Polysacchariden und Kaffesäurederivaten. Die letztere Stoffklasse stammt 
vom Shikimat-Biosyntheseweg und beinhaltet einige wichtige Moleküle für 
die Qualitätskontrolle von Echinaceaprodukten, wie Echinacosid und 
Cynarin, welche in der Literatur am häufigsten für die Standardisierung 
genannt werden und auch in der Industrie zu diesem Zweck weiten 
Gebrauch finden. Die Standardisierung von Heilmitteln ist von primärer 
Wichtigkeit, um Produkte auf den Markt zu bringen welche gleiche 
Wirkstoffgehalte von Produktionspartien aufweisen und diese auch auf der 
Packungsbeilage entsprechend wiedergeben. Diese Bedingung ist derzeit für 
mehrere Heilpflanzen nicht gegeben. Hinweise in der Literatur und aus einer 
vorhergehenden Arbeit in unserem Labor zeigen eine hohe Variabilität des 
Kaffesäurederivatgehaltes zwischen den verschiedenen Produktionspartien 
auf; eine solche Variabilität könnte auf eine unsachgemässe 
Nachernteverarbeitung und Extraktion zurückgeführt werden. Deswegen 
wurde diese Arbeit in Angriff genommen um i) den Einfluss der Verarbeitung 
des Pflanzenmaterials vor Extraktion und HPLC Analyse zu erläutern, ii) das 
Extraktionprotokoll zu prüfen und jenes schliesslich zu verbessern. In den 
ersten Experimenten wurde der Einfluss der Lager- und/oder 
Trocknungstemperatur auf den Kaffesäurederivatengehaltes von Blatt- und 
Wurzelgewebe von Echinacea angustifolia, welche im Gewächshaus 
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hydroponisch angebaut wurde, betrachtet. Die untersuchten Metaboliten 
waren: Echinacoside, Cynarin, Caftarsäure, Chlorogensäure und 
Chicoriensäure. Im Allgemeinen hatte die Trocknungstemperatur keinen allzu 
grossen Einfluss auf den Gehalt der gemessenen Polyphenole auf die 
Luftgetrockneten Proben, während der Gehalt in gefrorenen und 
gefriergetrockneten Proben sehr niedrig ausfiel. Die relativ tiefen 
Temperaturen die zum Trocknen des Pflanzenmaterials eingesetzt wurden, 
schliessen die Hypothese aus, dass in den gefrorenen und 
gefriergetrockneten Proben die Kaffesäurederivate an Zellkomponenten 
gebunden sind und diese durch den Trocknungsprozess für die analytische 
Erfassung verfügbar werden. Es ist wahrscheinlicher, dass eine Degradation 
der Metaboliten während des Extraktionsprozesses von gefrorenen Proben 
oder während des Gefriertrocknens erfolgt. Um diese Hypothese zu 
überprüfen, wurde das Extraktionsprotokoll abgeändert. In einem ersten 
Schritt durch die Zugabe des Extraktionslösemittels (Methanol-Wasser, 
70:30) vor dem homogenisieren des Pflanzengewebes. In einem zweiten 
Schritt wurde da Protokoll weiter abgeändert, durch die Säuerung des 
Extraktionslösemittels durch die Zugabe von Salzsäure 1%. Letztlich wurde 
der Verlust von Wirkstoffen durch den Einsatz von einem Internen Standard 
bestimmt (Gallusäure, ein Stoff welcher nicht in Echinaceagewebe 
vorkommt, wurde den Proben beigegeben). Die Extraktion von 
Kaffeesäurederivaten wurde verbessert durch di Abänderung der 
Extraktionsprotokolle und zeigte die besten Resultate für gefrorenes und 
gefriergetrocknetes Wurzelgewebe im Falle des gesäuerten Lösemittels. 
